

In re Application of: Francesca LEVI-SCHAFFER et al  
 Serial No.: 10/594,926  
 Filed: April 30, 2008  
 Office Action Mailing Date: March 30, 2011

Examiner: Nora Maureen ROONEY  
 Group Art Unit: 1644  
 Attorney Docket: 32379  
 Confirmation No.: 5770

**In the Claims:**

1-41. (Cancelled)

42. (Previously presented) A bi-specific antibody comprising:

(i) a first target recognition component which specifically binds to the inhibitory receptor IRp60; and

(ii) a second target recognition component which specifically binds to a marker specific for a mast cell, an eosinophil and/or a basophil, said marker being selected from the group consisting of IgE, cKIT, CCR3, IL-5R and FcεR1.

43. (Previously Presented) The bi-specific antibody of claim 42, wherein a binding of said antibody to said cell inhibits allergic-type reactions.

44. (Previously Presented) The bi-specific antibody of claim 42, wherein said first and second target recognition components are linked via any one of a cross-linker, a linker compound, a carrier, a synthetic spacer, an immobilizing substrate and a (Gly<sub>4</sub>Ser)<sub>3</sub> motif based flexible region.

45. (Previously Presented) The bi-specific antibody of claim 42, wherein said first and second target recognition components are cross-linked.

46. (Cancelled)

47. (Previously Presented) The bi-specific antibody of claim 42, wherein said recognition component is selected from any one of a naturally occurring, synthetic or recombinant antibody, single chain Fv (scFv), bi-functional scFv, diabody, F(ab) unit, F(ab') unit, bi-specific F(ab') conjugate, chemically

In re Application of: Francesca LEVI-SCHAFFER et al  
 Serial No.: 10/594,926  
 Filed: April 30, 2008  
 Office Action Mailing Date: March 30, 2011

Examiner: Nora Maureen ROONEY  
 Group Art Unit: 1644  
 Attorney Docket: **32379**  
 Confirmation No.: 5770

cross-linked bi-functional antibody, linear antibody or a F(ab')<sub>2</sub> antigen binding fragment of an antibody.

48. (Previously Presented) The bi-specific antibody of claim 42, wherein said recognition component is a F(ab') unit.

49. (Cancelled)

50. (Previously Presented) A pharmaceutical composition comprising as an active agent the bi-specific antibody of claim 42.

51. (Previously Presented) The pharmaceutical composition of claim 50, further comprising buffers, additives, stabilizers, diluents and/or excipients.

52. (Currently Amended) A method of treating an allergy, the method comprising administering to a subject in need thereof a therapeutically effective amount of ~~the bi-specific antibody of claim 42~~ comprising:

(i) a first target recognition component which specifically binds to the inhibitory receptor IRp60; and

(ii) a second target recognition component which specifically binds to a marker specific for a mast cell, an eosinophil and/or a basophil, said marker being selected from the group consisting of IgE, cKIT and CCR3;

thereby treating the allergy.

53-55.(Canceled)